209 related articles for article (PubMed ID: 15155827)
1. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
[TBL] [Abstract][Full Text] [Related]
2. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Hicks LD; Hyatt JL; Stoddard S; Tsurkan L; Edwards CC; Wadkins RM; Potter PM
J Med Chem; 2009 Jun; 52(12):3742-52. PubMed ID: 19534556
[TBL] [Abstract][Full Text] [Related]
3. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
4. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.
Hatfield MJ; Tsurkan L; Garrett M; Shaver TM; Hyatt JL; Edwards CC; Hicks LD; Potter PM
Biochem Pharmacol; 2011 Jan; 81(1):24-31. PubMed ID: 20833148
[TBL] [Abstract][Full Text] [Related]
5. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
6. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
7. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
8. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
10. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
11. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
13. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
14. Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1.
Hyatt JL; Wadkins RM; Tsurkan L; Hicks LD; Hatfield MJ; Edwards CC; Ross CR; Cantalupo SA; Crundwell G; Danks MK; Guy RK; Potter PM
J Med Chem; 2007 Nov; 50(23):5727-34. PubMed ID: 17941623
[TBL] [Abstract][Full Text] [Related]
15. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
17. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Alimonti A; Gelibter A; Pavese I; Satta F; Cognetti F; Ferretti G; Rasio D; Vecchione A; Di Palma M
Cancer Treat Rev; 2004 Oct; 30(6):555-62. PubMed ID: 15325035
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of carboxylesterases by isatins, indole-2,3-diones.
Hyatt JL; Moak T; Hatfield MJ; Tsurkan L; Edwards CC; Wierdl M; Danks MK; Wadkins RM; Potter PM
J Med Chem; 2007 Apr; 50(8):1876-85. PubMed ID: 17378546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]